These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16129776)

  • 21. Use of recursion forests in the sequential screening process: consensus selection by multiple recursion trees.
    van Rhee AM
    J Chem Inf Comput Sci; 2003; 43(3):941-8. PubMed ID: 12767153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A method with flexible and balanced control of false negatives and false positives for hit selection in RNA interference high-throughput screening assays: a statistical terminology.
    Schechtman E
    J Biomol Screen; 2008 Apr; 13(4):309-11. PubMed ID: 18413895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assay development and screening of human DGAT1 inhibitors with an LC/MS-based assay: application of mass spectrometry for large-scale primary screening.
    Zhang JH; Roddy TP; Ho PI; Horvath CR; Vickers C; Stout S; Hubbard B; Wang YK; Hill WA; Bojanic D
    J Biomol Screen; 2010 Jul; 15(6):695-702. PubMed ID: 20484097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Robust statistical methods for hit selection in RNA interference high-throughput screening experiments.
    Zhang XD; Yang XC; Chung N; Gates A; Stec E; Kunapuli P; Holder DJ; Ferrer M; Espeseth AS
    Pharmacogenomics; 2006 Apr; 7(3):299-309. PubMed ID: 16610941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Affinity ligand selection from a library of small molecules: assay development, screening, and application.
    Saraswat LD; Zhang H; Hardy LW; Jones SS; Bhikhabhai R; Brink C; Bergenstråhle A; Haglund R; Gallion SL
    Biotechnol Prog; 2005; 21(1):300-8. PubMed ID: 15903269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of ligands for Nurr1 by combined use of NMR screening with different isotopic and spin-labeling strategies.
    Poppe L; Harvey TS; Mohr C; Zondlo J; Tegley CM; Nuanmanee O; Cheetham J
    J Biomol Screen; 2007 Apr; 12(3):301-11. PubMed ID: 17438066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An empirical process for the design of high-throughput screening deck filters.
    Pearce BC; Sofia MJ; Good AC; Drexler DM; Stock DA
    J Chem Inf Model; 2006; 46(3):1060-8. PubMed ID: 16711725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A homogeneous time-resolved fluorescence-based high-throughput screening system for discovery of inhibitors of IKKbeta-NEMO interaction.
    Gotoh Y; Nagata H; Kase H; Shimonishi M; Ido M
    Anal Biochem; 2010 Oct; 405(1):19-27. PubMed ID: 20522330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A miniaturized cell-based fluorescence resonance energy transfer assay for insulin-receptor activation.
    Marine S; Zamiara E; Smith ST; Stec EM; McGarvey J; Kornienko O; Jiang G; Wong KK; Stack JH; Zhang BB; Ferrer M; Strulovici B
    Anal Biochem; 2006 Aug; 355(2):267-77. PubMed ID: 16797469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Automated multiple ligand screening by frontal affinity chromatography-mass spectrometry (FAC-MS).
    Ng W; Dai JR; Slon-Usakiewicz JJ; Redden PR; Pasternak A; Reid N
    J Biomol Screen; 2007 Mar; 12(2):167-74. PubMed ID: 17218664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing HTS performance using BioAssay Ontology: screening and analysis of a bacterial phospho-N-acetylmuramoyl-pentapeptide translocase campaign.
    Moberg A; Zander Balderud L; Hansson E; Boyd H
    Assay Drug Dev Technol; 2014; 12(9-10):506-13. PubMed ID: 25415593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plate-based diversity selection based on empirical HTS data to enhance the number of hits and their chemical diversity.
    Sukuru SC; Jenkins JL; Beckwith RE; Scheiber J; Bender A; Mikhailov D; Davies JW; Glick M
    J Biomol Screen; 2009 Jul; 14(6):690-9. PubMed ID: 19531667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Affinity-based screening techniques for enhancing lead discovery.
    Comess KM; Schurdak ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel statistical approach for primary high-throughput screening hit selection.
    Yan SF; Asatryan H; Li J; Zhou Y
    J Chem Inf Model; 2005; 45(6):1784-90. PubMed ID: 16309285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of Titration-Based Screening for the Rapid Pilot Testing of High-Throughput Assays.
    Zhang JH; Kang ZB; Ardayfio O; Ho PI; Smith T; Wallace I; Bowes S; Hill WA; Auld DS
    J Biomol Screen; 2014 Jun; 19(5):651-60. PubMed ID: 24246376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistics and decision making in high-throughput screening.
    Coma I; Herranz J; Martin J
    Methods Mol Biol; 2009; 565():69-106. PubMed ID: 19551358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Median absolute deviation to improve hit selection for genome-scale RNAi screens.
    Chung N; Zhang XD; Kreamer A; Locco L; Kuan PF; Bartz S; Linsley PS; Ferrer M; Strulovici B
    J Biomol Screen; 2008 Feb; 13(2):149-58. PubMed ID: 18216396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimizing false positives in kinase virtual screens.
    Perola E
    Proteins; 2006 Aug; 64(2):422-35. PubMed ID: 16708364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of non-peptidic neuromedin U receptor modulators by a robust homogeneous screening assay.
    Meng T; Su HR; Binkert C; Fischli W; Zhou L; Shen JK; Wang MW
    Acta Pharmacol Sin; 2008 Apr; 29(4):517-27. PubMed ID: 18358099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.